Skip to Content

DATATRAK to Feature CTMS and Full Platform at Upcoming DIA 2016

Simplify Clinical Trials with Responsive Software and Pure Integration

CLEVELAND, June 16 /PRNewswire/ DATATRAK International, Inc. (OTC Markets: DTRK), a leader in cloud-based, unified digital clinical technologies and related services for the clinical trials industry, today announced the full DATATRAK platform with an emphasis on the new CTMS solution, UX CTMS 360™, will be featured at DIA 2016. “We have really raised the bar in terms of what can be expected from a CTMS solution,” said Jim Bob Ward, CEO and President, DATATRAK. “Clients can view and analyze their stored data within and across trials, at the site, trial, or enterprise level. Our UX CTMS 360™ software is pre-configured, so you can get started right away. Additional configuration can be completed through the interface, pre- and post-deployment, without the need for technology expertise. We have simplified the management of regulatory submission, automating the tracking of submissions and their status. No need for manual redundant processes. Our CTMS solution integrates with all EDC solutions so you can easily realize these great benefits for your trials. UX CTMS 360 empowers users to make informed decisions faster, safely accelerating their trials.” “UX CTMS 360 was designed to realize actual operational efficiency from day one,” said Tim Lyons, Vice President Operations, DATATRAK. “Our solution empowers clinical teams to manage their trials independent of technical consultants. So not only can you get started faster, you eliminate high costs and lengthy timelines to set-up the software.  This great addition to the DATATRAK platform is another example of our steadfast focus to safely accelerate drugs, devices and biologics to market.” “One of the most impressive benefits of all of our solutions is how they work together,” said Scott DeMell, Vice President Sales, DATATRAK. “Our highly configurable software can adapt to the unique needs of each trial. From CTMS to EDC, to Randomization and Trial Supply Management, our software easily adapts to each trial as stand-alone solutions, as a full platform, or anything in between. Our software is purpose built to work seamlessly together, eliminating the need for integration. There is only one set of data to manage. That means our clients eliminate redundancy and improve the quality of their data right from the start.” DATATRAK will exhibit at DIA 2016 in booth #1154. Book an appointment to see how DATATRAK can simplify your clinical trials with responsive software. Twitter: See how responsive software can simplify #clinicaltrials Book a demo at #DIA2016 Our #CTMS solution gives you 360 data views to make informed decisions faster. Book a demo at #DIA2016   Join DATATRAK Thought Leaders:   About DATATRAK International, Inc. DATATRAK International is a worldwide technology and services company delivering unified dClinical® solutions and related services for the clinical trials industry. DATATRAK built its multi-component, comprehensive solution on a single, unified platform and expanded this concept to include services delivery via DATATRAK’s Clinical and Consulting Services group. The Company delivers a complete portfolio of software products designed to accelerate the reporting of clinical research data from sites to sponsors and ultimately regulatory authorities, faster and more efficiently than loosely integrated technologies. The DATATRAK ONE® software solution, deployed worldwide through an ASP or Enterprise Transfer offering, supports Preclinical and Phase I - Phase IV drug and device studies in multiple languages throughout the world. DATATRAK is located in Chicago, Illinois; Cleveland, Ohio; and Bryan, Texas.  For more information, visit Except for the historical information contained in this press release, the statements made in this release are forward-looking statements. These forward-looking statements are made based on management’s expectations, assumptions, estimates and current beliefs concerning the operations, future results and prospects of the Company and are subject to uncertainties and factors which are difficult to predict and, in many instances, are beyond the control of the Company, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. For a list of certain factors that may cause actual results to differ materially from those contemplated in these forward looking statements, please see the Company’s report filed with the OTC Markets on April 8, 2016 announcing its results for the full-year period ended December 31, 2015. The Company undertakes no obligation to update publicly or revise any forward-looking statement whether as a result of new information, future events or otherwise.   Contacts: Sales: Scott DeMell Employment Opportunities: Laura Stuebbe Shareholders: Alex Tabatabai